Boehringer Ingelheim International Gmbh

Boehringer Ingelheim (canada) Ltd.

Gilead Sciences, Inc.

Bio-mega/boehringer Ingelheim Research Inc.

Other

Boehringer Ingelheim Pharmaceuticals, Inc.

Universitéde Montreal

Biomega, Inc.

Boehringer Ingelheim Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Boehringer Ingelheim International Gmbh & Co., Kg

William W. Ogilvie

Bruno Simoneau

Jeffrey O'meara

Robert Deziel

Christiane Yoakim

Youla S Tsantrizos

Serge R Landry

Murray D Bailey

Anne-Marie Faucher

Bounkham Thavonekham

Jeffrey O'Meara

Teddy Halmos

Lee Fader

Stephen Kawai

Sebastien Morin

Rebekah J Carson

Karl D Hargrave

Marc-Andre Poupart

Paul C Anderson

Francois Bilodeau

Mathieu Parisien

Patrick Deroy

Christine A Grygon

Jean Rancourt

William W Ogilvie

Alexandre Gagnon

Montse Llinas-Brunet

Nathalie Goudreau

Elise Ghiro

Dominik M Wernic

Carl Thibeault

Christian Brochu

Simon Surprenant

Pierre Lavallee

Robert D&eacute;ziel

Anton Mentrup

Pierre Louis Beaulieu

Martin Duplessis

Clint A James

Claudio F Sturino

Anne Marinier

Gulrez Fazal

Marc-André Poupart

Grace L Jung

James J Crute

Steven LaPlante

Rene Coulombe

Marc-Andr E Poupart

Dale Cameron

Marc-Andr&eacute; Poupart

Steven R Laplante

Guy Sauvageau

Paul John Edwards

Julie Naud

Eric Malenfant

Jean-Eric Lacoste

Josee Bordeleau

Martin Tremblay

Yves Chantigny

Louis Morency

Pierre Lavall Ee

Araz Jakalian

Robert Déziel

Joannie Minville

Sébastien Morin

François Bilodeau

Michele Liuzzi

J James Crute

Gary W Bantle

Steven Laplantea

Steve Mason

Pierre Bonneau

Jeffrey O′Meara

Punit K Bhardwaj

Punit-Kumar Bhardwaj

Jonathan Yeh

Josée Bordeleau

Claudio Sturino

Paul J Edwards

René Coulombe

Jeffrey O'MEARA

The invention relates to compounds as described herein and pharmaceutical compositions containing them. Also, the invention relates to methods for expanding stem cells and/or progenitor cells and methods for treating a hematopoietic disorder/malignancy, an autoimmune disease and/or an inherited immunodeficient disease.

Compounds and use thereof in the expansion of stem cells and/or progenitor cells

Compounds of formula (I) and pharmaceutical compositions thereof: wherein AAand Aare each independently selected from the group consisting of N and CR, wherein Ris an optionally substituted heterocyclyl or an optionally substituted &#x2014;(C)alkyl-heterocyclyl, Ris an optionally substituted aryl or an optionally subsisted heteroaryl, Ris an optionally substituted aryl, an optionally substituted heterocyclyl or an optionally substituted heteroaryl, useful as an inhibitor of HIV replication. 

Inhibitors of HIV replication

Compounds of formula I: wherein a, R, R, R, R, Rand Rare defined herein, are useful as inhibitors of HIV replication.

Inhibitors of human immunodeficiency virus replication

Compounds of formula I: wherein R, Rand Rare defined herein, are useful as inhibitors of HIV replication.

Compounds of formula (I): wherein c, X, Y, R, Rand Rare defined herein, are useful as inhibitors of HIV replication. 

Compounds of formula I: wherein c, R, R, R, R, R, Rand Rare defined herein, are useful as inhibitors of HIV replication. 

Compounds of formula (I): wherein Ar, X, R, R, Rand Rare as defined herein. The compounds are useful as reverse transcriptase inhibitors against wild type and single or double mutant strains of HIV.

Non-nucleoside reverse transcriptase inhibitors

The present invention relates to compounds of formula (I) wherein c, X, Y, R, R, Rand Rare as defined herein, compositions and uses thereof for treating human immunodeficiency virus (HIV) infection. In particular, the present invention provides novel inhibitors of HIV integrase, pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HIV infection.

Disclosed herein are compounds of formula Ar&#x2014;X&#x2014;W&#x2014;Arwherein Arand Arrepresent aryl groups characterized generally as aromatic heterocycles (e.g. imidazolyl or tetrazolyl) or carbocycles (e.g. phenyl or naphthalenyl); the aryl groups are optionally substituted or fused with other heterocycles or carbocycles; the aryl groups can bear substituents such as alkyl, halo or O-alkyl. X is a heteroatom, a valence bond or an optionally substituted divalent methylene, and W represents a spacer; typical spacers include divalent alkylene or alkylene-amido, -amido or -oxy radicals, which may optionally be substituted (e.g. hydroxyl or oxo). A typical compound is a derivative of 2-(N-napthalenyltetrazolylthio)-N-(2-nitrophenyl)acetamide. The compounds have inhibitory activity against Wild Type and single or double mutant strains of HIV.

Compounds of formula (I): wherein R, R, R, R, Rand Rare as defined herein. The compounds are useful as reverse transcriptase inhibitors against HIV. In particular, the compounds are active against wild type and single or double mutant strains of HIV.

Benzoic acid derivatives as non nucleoside reverse-transcriptase inhibitors

Non nucleoside reverse transcriptase inhibitors

Compounds or enantiomers of formula (I) or a salt thereof: wherein R, R, R, Rand Rare as defined herein, are useful for the manufacture of a medicament for the treatment or prevention of respiratory syncytial virus infection in a mammal.

RSV polymerase inhibitors

Inhibitors of HIV reverse transcriptase which are useful for the treatment of HIV infection. Exemplars of the invention are compounds of the formula wherein the substituents are as defined in the following table 

Alkynyl compounds as non nucleoside reverse transcriptase inhibitors

Growing community of inventors

Laval, Canada

Bruno Simoneau